Elite Pharmaceuticals (ELTP)
OTHER OTC:ELTP
Top Page
Elite Pharmaceuticals
(OTC:ELTP)
Select Model
Select Model
Rating:70Outperform
Price Target:
$0.42
▼(-11.70% Downside)
Action:ReiteratedDate:04/03/26
The score is driven primarily by strong TTM financial performance (high margins, low leverage, and positive free cash flow) and supportive recent corporate updates. These positives are tempered by weak technical positioning (below key moving averages with negative MACD) and historical variability in reported results, while valuation appears favorable with a low P/E.
Positive Factors
Strong TTM profitability
Sustained high TTM margins and positive operating performance indicate durable earnings power from product mix and manufacturing leverage. This improves cash generation potential, funds reinvestment in R&D and commercial launches, and supports resilience versus typical generic pricing pressure.
Negative Factors
Earnings volatility
Material swings year-to-year reduce predictability of core earnings and complicate planning for capacity and R&D. Reliance on episodic product launches and variable contract volumes raises execution risk and weakens confidence in long-term earnings stability.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong TTM profitability
Sustained high TTM margins and positive operating performance indicate durable earnings power from product mix and manufacturing leverage. This improves cash generation potential, funds reinvestment in R&D and commercial launches, and supports resilience versus typical generic pricing pressure.
Read all positive factors
Elite Pharmaceuticals (ELTP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$409.15M
Dividend YieldN/A
Average Volume (3M)951.20K
Price to Earnings (P/E)7.1
Beta (1Y)1.48
Revenue Growth72.67%
EPS GrowthN/A
CountryUS
Employees64
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)<0.01
Shares Outstanding1,076,996,500
10 Day Avg. Volume753,540
30 Day Avg. Volume951,200
Financial Highlights & Ratios
PEG Ratio0.90
Price to Book (P/B)8.68
Price to Sales (P/S)5.53
P/FCF Ratio94.25
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue2.81
Enterprise Value/Gross Profit5.51
Enterprise Value/Ebitda8.61
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Elite Pharmaceuticals Business Overview & Revenue Model
Company Description
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and manufacture of oral, controlled-release products and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications f...
How the Company Makes Money
Elite Pharmaceuticals primarily makes money through: (1) Sales of generic pharmaceutical products: Revenue is generated by selling company-developed or company-commercialized generic drugs to wholesale/distribution channels and other customers; pr...
Elite Pharmaceuticals Earnings Call Summary
Earnings Call Date:Nov 14, 2025
(Q2-2026)
| % Change Since: |
Next Earnings Date:Jul 06, 2026
Earnings Call Sentiment Positive
Elite Pharmaceuticals reported strong revenue growth and improved operating profits, driven by increased market share and a robust product pipeline. However, increased competition has affected profit margins, and higher administrative costs have been noted. The company's balance sheet remains strong, but market dynamics could present challenges.Positive Updates
Record Revenue Growth
Total revenues for the quarter were $36.3 million, a 92% increase compared to $18.8 million for the September 2024 quarter. Revenues for the first six months of fiscal 2026 were $76.5 million, a 103% increase compared to $37.7 million for the same period last year.
Negative Updates
Increased Competition Affecting Margins
Price competition for Lisdexamfetamine and generic Vyvanse products led to lower revenues and profits compared to the previous quarter, despite increased volumes.
Read all updates
Q2-2026 Updates
Positive
Negative
Record Revenue Growth
Total revenues for the quarter were $36.3 million, a 92% increase compared to $18.8 million for the September 2024 quarter. Revenues for the first six months of fiscal 2026 were $76.5 million, a 103% increase compared to $37.7 million for the same period last year.
Read all positive updates
Company Guidance
During Elite Pharmaceuticals' second-quarter fiscal year 2026 conference call, significant growth metrics were highlighted. The company reported a 92% year-over-year revenue increase for the quarter ending September 2025, with revenues reaching $36.3 million compared to $18.8 million the previous year. Additionally, the first six months of fiscal 2026 saw revenues of $76.5 million, marking a 103% increase from $37.7 million in the same period of the previous year. Elite's operating profit surged by 136% to $8.2 million for the quarter, and cash flow from operations rose by 333% to $19.9 million. The company's robust performance was attributed to its well-established market presence and successful product launches, including the Lisdexamfetamine line. Furthermore, Elite's balance sheet showed strengthening trends with working capital increasing by 63% to $75 million, driven by rising current assets and decreasing liabilities.Elite Pharmaceuticals Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
90
Very Positive
Cash Flow
72
Positive
| Breakdown | TTM | Jun 2025 | Jun 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 140.12M | 84.04M | 56.63M | 34.16B | 32.26M | 25.38M |
| Gross Profit | 71.55M | 40.09M | 26.36M | 16.59B | 14.80M | 11.87M |
| EBITDA | 45.77M | 2.84M | 2.52M | 6.43M | 6.49M | 3.63M |
| Net Income | 43.41M | -4.31M | 20.11M | 4.41B | 8.90M | 5.09M |
Balance Sheet | ||||||
| Total Assets | 126.41M | 96.39M | 83.65M | 40.90M | 35.15M | 26.19M |
| Cash, Cash Equivalents and Short-Term Investments | 21.09M | 11.32M | 7.11M | 7.83M | 8.54M | 3.19M |
| Total Debt | 7.21M | 10.91M | 11.74M | 3.89M | 2.78M | 2.38M |
| Total Liabilities | 46.10M | 42.87M | 26.07M | 11.94M | 9.93M | 10.04M |
| Stockholders Equity | 80.31M | 53.52M | 57.58M | 28.96M | 25.22M | 16.15M |
Cash Flow | ||||||
| Free Cash Flow | 17.24M | 4.93M | -4.09M | -2.40M | 6.01M | 2.86M |
| Operating Cash Flow | 18.52M | 7.46M | -3.28M | 3.34M | 6.51M | 3.19M |
| Investing Cash Flow | -1.28M | -2.40M | -809.65K | -5.74M | -498.57K | -262.78K |
| Financing Cash Flow | -4.42M | -825.74K | 3.39M | 1.70M | -667.13K | -869.83K |
Elite Pharmaceuticals Technical Analysis
Negative
0.47
Price Trends
0.40
Negative
0.45
Negative
0.53
Negative
Market Momentum
>-0.01
Negative
40.88
Neutral
53.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELTP, the sentiment is Negative. The current price of 0.47 is above the 20-day moving average (MA) of 0.38, above the 50-day MA of 0.40, and below the 200-day MA of 0.53, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 40.88 is Neutral, neither overbought nor oversold. The STOCH value of 53.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ELTP.
Elite Pharmaceuticals Risk Analysis
Elite Pharmaceuticals disclosed 40 risk factors in its most recent earnings report. Elite Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Elite Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $409.15M | 7.08 | 71.43% | ― | 72.67% | ― | |
67 Neutral | $312.37M | 18.78 | 11.26% | ― | -0.85% | -13.50% | |
61 Neutral | $924.19M | 12.76 | 12.76% | ― | -0.03% | -27.66% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $306.16M | 17.73 | 9.56% | ― | 2.24% | -67.56% | |
48 Neutral | $497.94M | -9.40 | 195.65% | ― | -26.32% | -56.54% |
* Healthcare Sector Average
ELTP
Elite Pharmaceuticals
0.38
-0.03
-7.56%
SIGA
SIGA Technologies
4.36
-0.41
-8.60%
AMPH
Amphastar Pharmaceuticals
20.37
-3.79
-15.69%
ORGO
Organogenesis Holdings
2.38
-1.88
-44.13%
AQST
Aquestive Therapeutics
4.08
1.61
65.18%
Elite Pharmaceuticals Corporate Events
Business Operations and StrategyProduct-Related Announcements
Elite launches generic methadone tablets, expanding pain portfolio
Positive
Apr 2, 2026
On April 2, 2026, Elite Pharmaceuticals announced it has commercially launched its generic methadone hydrochloride 5 mg and 10 mg tablets in the United States under the Elite Laboratories, Inc. label. The tablets, indicated for severe and persiste...
Business Operations and StrategyFinancial Disclosures
Elite Pharmaceuticals Delivers Strong Fiscal Q3 2026 Results
Positive
Feb 17, 2026
Elite Pharmaceuticals reported strong financial performance for its third quarter of fiscal 2026, covering the three months ended Dec. 31, 2025, highlighted by a sharp jump in revenue and profitability. Consolidated revenues reached $31.6 million,...
Business Operations and StrategyFinancial Disclosures
Elite Pharmaceuticals Schedules Q3 Fiscal 2026 Results Call
Neutral
Feb 11, 2026
Elite Pharmaceuticals, Inc., a specialty generics developer based in Northvale, N.J., focuses on immediate-release and controlled-release solid oral dose products, which it markets under its Elite Laboratories label and through licensed third-part...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.